Cargando…

Inflammatory and Hypercoagulable Biomarkers and Clinical Outcomes in COVID-19 Patients

Systemic inflammation and hypercoagulopathy are known pathophysiological processes of coronavirus disease 2019 (COVID-19), particularly in patients with known cardiovascular disease or its risk factors (CVD). However, whether a cumulative assessment of these biomarkers at admission could contribute...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitakata, Hiroki, Kohsaka, Shun, Kuroda, Shunsuke, Nomura, Akihiro, Kitai, Takeshi, Yonetsu, Taishi, Torii, Sho, Matsue, Yuya, Matsumoto, Shingo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304719/ https://www.ncbi.nlm.nih.gov/pubmed/34300252 http://dx.doi.org/10.3390/jcm10143086

Ejemplares similares

Impact of body mass index on the outcome of Japanese patients with cardiovascular diseases and/or risk factors hospitalized with COVID-19 infection
por: Saito, Takafumi, et al.
Publicado: (2022)

Sex Differences in Clinical Outcomes Among Patients With COVID-19 and Cardiovascular Disease　― Insights From the CLAVIS-COVID Registry ―
por: Matsumoto, Shingo, et al.
Publicado: (2022)

Predictive value of neutrophil-to-lymphocyte ratio for the fatality of COVID-19 patients complicated with cardiovascular diseases and/or risk factors
por: Higaki, Akinori, et al.
Publicado: (2022)

External validation of the 4C Mortality Score for patients with COVID-19 and pre-existing cardiovascular diseases/risk factors
por: Kuroda, Shunsuke, et al.
Publicado: (2021)

Assessment of thromboembolism risk in COVID-19 patients with cardiovascular disease risk factors: Analysis of a Japanese Nationwide Registry()
por: Shibahashi, Eiji, et al.
Publicado: (2022)

Impact of serum lactate dehydrogenase on the short-term prognosis of COVID-19 with pre-existing cardiovascular diseases
por: Masumoto, Akiko, et al.
Publicado: (2022)

Intensive Care Unit Admission for Moderate-to-Severe COVID-19 Patients With Known Cardiovascular Diseases or Their Risk Factors　― Insights From a Nationwide Japanese Cohort Study ―
por: Yoshida, Naofumi, et al.
Publicado: (2021)

9‐Year Trend in the Management of Acute Heart Failure in Japan: A Report From the National Consortium of Acute Heart Failure Registries
por: Shiraishi, Yasuyuki, et al.
Publicado: (2018)

Histological examination of the right atrial appendage after failed catheter ablation for focal atrial tachycardia complicated by cardiogenic shock in a post-partum patient
por: Mizukami, Akira, et al.
Publicado: (2016)

Biomarkers of Hypercoagulability in COVID-19
por: Wada, Hideo
Publicado: (2023)

Patient Perspectives in the Era of Remote Medical Visits During the Coronavirus Disease (COVID-19) Pandemic　― Insights From Outpatient Care of Cardiovascular Disease ―
por: Kitakata, Hiroki, et al.
Publicado: (2021)

Effect of the COVID-19 Pandemic on Acute Respiratory Care of Hypoxemic Patients With Acute Heart Failure in Japan　― A Cross-Sectional Study ―
por: Matsue, Yuya, et al.
Publicado: (2020)

Derivation and Validation of Clinical Prediction Models for Rapid Risk Stratification for Time-Sensitive Management for Acute Heart Failure
por: Shiraishi, Yasuyuki, et al.
Publicado: (2020)

Patient confidence regarding secondary lifestyle modification and knowledge of ‘heart attack’ symptoms following percutaneous revascularisation in Japan: a cross-sectional study
por: Kitakata, Hiroki, et al.
Publicado: (2018)

Impact of brain natriuretic peptide reduction on the worsening renal function in patients with acute heart failure
por: Yoshioka, Kenji, et al.
Publicado: (2020)

Hypercoagulability in Dogs with Blastomycosis
por: McMichael, M.A., et al.
Publicado: (2015)

A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms
por: Kobayashi, Mayu, et al.
Publicado: (2021)

Effectiveness of methotrexate as a second-line treatment for cardiac sarcoidosis assessed via (18)F-FDG PET: a case report
por: Dotare, Taishi, et al.
Publicado: (2022)

Preferences on advance care planning and end‐of‐life care in patients hospitalized for heart failure
por: Kitakata, Hiroki, et al.
Publicado: (2021)

Proteome Analysis of Urinary Biomarkers in Acute Hypercoagulable State Rat Model
por: Jing, Jian, et al.
Publicado: (2021)

Clinical implication of initial intravenous diuretic dose for acute decompensated heart failure
por: Yoshioka, Kenji, et al.
Publicado: (2022)

The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate
por: Matsumoto, Takeshi, et al.
Publicado: (2023)

Prognostic Implications of Early and Midrange Readmissions After Acute Heart Failure Hospitalizations: A Report From a Japanese Multicenter Registry
por: Kitakata, Hiroki, et al.
Publicado: (2020)

Familial Mediterranean Fever and Hypercoagulability
por: Tayer-Shifman, Oshrat E., et al.
Publicado: (2011)

Dipyrimadole & Post-Operative Hypercoagulability
por: Jayaswal, U.
Publicado: (1967)

Chronometric vs. Structural Hypercoagulability
por: Delianu, Carmen, et al.
Publicado: (2020)

Hypercoagulation in COPD: the clot thickens
por: Rahaghi, Farbod N., et al.
Publicado: (2021)

The Burden of Hypercoagulability in COVID-19
por: Kim, Madeleine, et al.
Publicado: (2022)

Hypercoagulability in pregnant trauma patients
por: Toelle, Lisa J, et al.
Publicado: (2021)

Thromboinflammation and the hypercoagulability of COVID‐19
por: Connors, Jean M., et al.
Publicado: (2020)

Social Isolation and Implementation of Advanced Care Planning Among Hospitalized Patients With Heart Failure
por: Kitakata, Hiroki, et al.
Publicado: (2022)

Advances in Intravascular Imaging: New Insights into the Vulnerable Plaque from Imaging Studies
por: Yonetsu, Taishi, et al.
Publicado: (2017)

The Prognostic Value of B‐Type Natriuretic Peptide in Patients With Cardiac Sarcoidosis Without Heart Failure: Insights From ILLUMINATE‐CS
por: Miyakuni, Shota, et al.
Publicado: (2022)

Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response
por: Pinazo, Maria-Jesus, et al.
Publicado: (2016)

The hypercoagulable states in anaesthesia and critical care
por: Bande, Bala D, et al.
Publicado: (2014)

The hypercoagulable profile of patients with stent thrombosis
por: Loeffen, R, et al.
Publicado: (2015)

Hypercoagulability in hereditary hemorrhagic telangiectasia with epilepsy
por: Finsterer, Josef, et al.
Publicado: (2015)

Serum hypercoagulability states in Coats’ disease
por: Ghassemi, Fariba, et al.
Publicado: (2017)

Monitoring of Hypercoagulability by Thromboelastography in Bariatric Surgery
por: Kupcinskiene, Kristina, et al.
Publicado: (2017)

COVID-19 and Hypercoagulability: A Review
por: Kichloo, Asim, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8pb43dcu8je8p3dg7ol9nnlogo